Stephen M. Stahl, M.D., Ph.D.

Efficacy and Safety of Iloperidone in Bipolar Mania

January 15, 2024

At 4 weeks of treatment, patients receiving iloperidone showed significant improvement on the Young Mania Rating Scale versus those receiving placebo.

Rosarelis Torres, Emily L. Czeisler, Sean R. Chadwick, et al

Original Research

Screening for Bipolar Disorder and Evaluating the RMS

April 25, 2023

Health care providers found the Rapid Mood Screener, a new bipolar I disorder screening tool, to be superior to the widely used Mood Disorder Questionnaire in sensitivity/specificity, brevity, practicality,...

Michael E. Thase, Stephen M. Stahl, Roger S. McIntyre, et al

Original Research

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

April 24, 2023

Lumateperone significantly improved depression symptoms, disease severity, and quality of life in patients with bipolar depression with mixed features.

Roger S. McIntyre, Suresh Durgam, Jason Huo, et al

Original Research

Need for New Atypical Antipsychotic Nomenclature

February 23, 2023

The current nomenclature for atypical antipsychotics does not convey that they are frequently prescribed to treat nonpsychotic indications, such as bipolar I mania, bipolar I depression, and MDD.

Greg Mattingly, Tina Matthews-Hayes, Mehul D. Patel, et al

Original Research

Effect of Adjunctive l-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial

April 15, 2014

George I. Papakostas, Richard C. Shelton, John M. Zajecka, et al

Original Research

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

March 13, 2013

Stephen M. Stahl, Josephine Cucchiaro, Doreen Simonelli, et al

Original Research

The Vasopressin V1b Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies

October 16, 2012

Guy Griebel, Sandra Beeské, Stephen M. Stahl

Brainstorms

The Serotonin-7 Receptor as a Novel Therapeutic Target

November 15, 2010

Stephen M. Stahl

Brainstorms

Illustrating the Circuits of Sexual Desire

September 15, 2010

Stephen M. Stahl

Brainstorms

Targeting Circuits of Sexual Desire as a Treatment Strategy for Hypoactive Sexual Desire Disorder

July 15, 2010

Stephen M. Stahl

Brainstorms

HSDD: Circuits of Sexual Desire/Inhibition

May 15, 2010

Understand what is Hypoactive Sexual Desire Disorder (HSDD) and what mesolimbic and hypothalamic circuits are turned on by sexual desire/inhibition.

Stephen M. Stahl

Original Research

Agomelatine in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter, Randomized, Placebo-Controlled Trial

March 23, 2010

Stephen M. Stahl, Maurizio Fava, Madhukar H. Trivedi, et al

Stephen M. Stahl, M.D., Ph.D.

Efficacy and Safety of Iloperidone in Bipolar Mania

Screening for Bipolar Disorder and Evaluating the RMS

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

Need for New Atypical Antipsychotic Nomenclature

Effect of Adjunctive l-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

The Vasopressin V1b Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies

The Serotonin-7 Receptor as a Novel Therapeutic Target

Illustrating the Circuits of Sexual Desire

Targeting Circuits of Sexual Desire as a Treatment Strategy for Hypoactive Sexual Desire Disorder

HSDD: Circuits of Sexual Desire/Inhibition

Agomelatine in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter, Randomized, Placebo-Controlled Trial

ELSEWHERE:

FOLLOW US:

Stephen M. Stahl, M.D., Ph.D.

Efficacy and Safety of Iloperidone in Bipolar Mania

Screening for Bipolar Disorder and Evaluating the RMS

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

Need for New Atypical Antipsychotic Nomenclature

Effect of Adjunctive l-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

The Vasopressin V1b Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studies

The Serotonin-7 Receptor as a Novel Therapeutic Target

Illustrating the Circuits of Sexual Desire

Targeting Circuits of Sexual Desire as a Treatment Strategy for Hypoactive Sexual Desire Disorder

HSDD: Circuits of Sexual Desire/Inhibition

Agomelatine in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter, Randomized, Placebo-Controlled Trial

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles